# TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

> **NCT03756818** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 52 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Ovarian Carcinoma
- Refractory Malignant Solid Neoplasm
- Refractory Ovarian Carcinoma

## Interventions

- **DRUG:** Mivavotinib
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacokinetic Study

## Key facts

- **NCT ID:** NCT03756818
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-05
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03756818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03756818, "TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03756818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*